Children's oncology group's 2013 blueprint for research

Bone tumors

Richard Gorlick, Katherine Janeway, Stephen Lessnick, R. Lor Randall, Neyssa Marina

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

Original languageEnglish (US)
Pages (from-to)1009-1015
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Ewing's Sarcoma
Osteosarcoma
Bone and Bones
Research
Neoplasms
Topotecan
Drug Therapy
Ifosfamide
Survival
Etoposide
Cyclophosphamide
Interferons
Neoplasm Metastasis
Pharmaceutical Preparations
Therapeutics

Keywords

  • Blueprint
  • Bone sarcoma
  • Ewing sarcoma
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., & Marina, N. (2013). Children's oncology group's 2013 blueprint for research: Bone tumors. Pediatric Blood and Cancer, 60(6), 1009-1015. https://doi.org/10.1002/pbc.24429

Children's oncology group's 2013 blueprint for research : Bone tumors. / Gorlick, Richard; Janeway, Katherine; Lessnick, Stephen; Randall, R. Lor; Marina, Neyssa.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 06.2013, p. 1009-1015.

Research output: Contribution to journalArticle

Gorlick, R, Janeway, K, Lessnick, S, Randall, RL & Marina, N 2013, 'Children's oncology group's 2013 blueprint for research: Bone tumors', Pediatric Blood and Cancer, vol. 60, no. 6, pp. 1009-1015. https://doi.org/10.1002/pbc.24429
Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N. Children's oncology group's 2013 blueprint for research: Bone tumors. Pediatric Blood and Cancer. 2013 Jun;60(6):1009-1015. https://doi.org/10.1002/pbc.24429
Gorlick, Richard ; Janeway, Katherine ; Lessnick, Stephen ; Randall, R. Lor ; Marina, Neyssa. / Children's oncology group's 2013 blueprint for research : Bone tumors. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 1009-1015.
@article{baab49e7696a4a2089470653a5da9a1b,
title = "Children's oncology group's 2013 blueprint for research: Bone tumors",
abstract = "In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65{\%} to 75{\%} for localized disease and <30{\%} for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.",
keywords = "Blueprint, Bone sarcoma, Ewing sarcoma, Osteosarcoma",
author = "Richard Gorlick and Katherine Janeway and Stephen Lessnick and Randall, {R. Lor} and Neyssa Marina",
year = "2013",
month = "6",
doi = "10.1002/pbc.24429",
language = "English (US)",
volume = "60",
pages = "1009--1015",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Children's oncology group's 2013 blueprint for research

T2 - Bone tumors

AU - Gorlick, Richard

AU - Janeway, Katherine

AU - Lessnick, Stephen

AU - Randall, R. Lor

AU - Marina, Neyssa

PY - 2013/6

Y1 - 2013/6

N2 - In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

AB - In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

KW - Blueprint

KW - Bone sarcoma

KW - Ewing sarcoma

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84876421334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876421334&partnerID=8YFLogxK

U2 - 10.1002/pbc.24429

DO - 10.1002/pbc.24429

M3 - Article

VL - 60

SP - 1009

EP - 1015

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -